Criteria for cycle cancellation at the day of hCG administration were either inability to reach the hCG criterion or >25 follicles with a diameter of ≥10 mm.
In the following sections I describe four categories, emphasizing that any attempt to describe one authenticity criterion inevitably cycles through descriptions of the others.
As a quantitative basis for selecting the ASP criteria, life cycle assessments (LCAs) were performed between 2011 and 2013 to identify the most relevant environmental impacts per product category.
Response was assessed by CT according to WHO criteria after cycle 3 and 6; in addition, tumour marker CA-125 was used to monitor response and was measured before each cycle.
Secondary objectives were to compare tumor response by CT (RECIST 1.0) and FDG-PET/CT (EORTC criteria) following cycle 1, and determine TTP with continued cetuximab administration in patients with disease control by CT after cycle 1 but stratified for disease control or progression by FDG-PET/CT.
The criteria for cycle cancellation were as follows: (a) premature luteinizing hormone (LH) surge; (b) during COH, LH > 12 mIU/mL; (c) decrease in the level of E2 (more than 50% between 2 control days); (d) patients who failed to respond despite stimulation for 6 days; and (e) the inability to retrieve oocytes or the underdevelopment of the embryo.
A systems modeling framework is presented, with integrates engineering criteria, life-cycle environmental data, aircraft fleet stock and fuel use models under different AM adoption scenarios.
Based on our exclusion criteria, 157 cycles were excluded for a variety of medical and non-medical reasons (see results in Supporting Information Text S1 for details).
Specifically, optimal design problems for the cycle criterion are established and compared with optimal models related to the asymptotic criterion.
This paper is focused on such controlled systems but with the cycle criterion.
